La cadena de opciones muestra datos clave de las opciones de acciones de ZK International Gr Co a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ZK International Gr Co..

ZK International Gr Co (NASDAQ:ZKIN) Bolsa, Cadena de Opciones

ZK International Gr Co

ZK International Group Co Ltd is engaged in the manufacture and marketing of metal pipes. The company is specialized in producing double-press thin-walled stainless steel tubes and fittings, carbon steel tubes and fittings, single-press tubes and fittings, and stainless-steel strips. The products are used in restaurants, hotels, hospitals, firefighting, food, beverage, ships, engines, industrial seawater desalination and systems of direct-drinking water, cold /hot water supply, city water supply, and gas of large/middle scale construction projects.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

ZK International Group Co., Ltd - Ordinary Share

ZK International Group Co Ltd

Piper Sandler analyst Paul Newsome upgrades Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) from Neutral to Overweight and lowers the price target from $384 to $378.

News

Upgrades

Price Target

Analyst Ratings

Piper Sandler Upgrades Aon to Overweight, Lowers Price Target to $378

Citigroup analyst Michael Rollins maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Buy and raises the price target from $425 to $445.

CHTR

Citigroup Maintains Buy on Charter Communications, Raises Price Target to $445

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Outperform and lowers the price target from $371 to $366.

Keefe, Bruyette & Woods Maintains Outperform on Willis Towers Watson, Lowers Price Target to $366

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="582" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-1024x582.jpg" alt="" class="wp-image-11680" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-1024x582.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-300x171.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster-768x436.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071043/Roller-Coaster.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">We&#8217;re In A Bear Market, And Stocks Have Further To Fall</h2>
That&#8217;s been our basic thesis since early this month. Big market participants (such as Bill Ackman) thought Trump&#8217;s tariffs were a negotiating tack or a bluff. Ergo, the extent of them wasn&#8217;t priced in, and when it was, we would go lower.&nbsp;
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/the-64-trillion-question"><img loading="lazy" decoding="async" width="922" height="861" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion.jpg" alt="" class="wp-image-11681" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion.jpg 922w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion-300x280.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071148/64-Trillion-768x717.jpg 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
Whether it makes sense to balance trade is a separate question. We think it does, as does Warren Buffett and as did the late Intel CEO, Andy Grove. But even if it&#8217;s a good policy, there is going to be a period of painful adjustment.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The warnings from public trucking companies, including LTL providers, tells us that the Trade War is about to take a massive toll on the economy. Most Americans are blissfully ignorant that Main Street activity has sharply down shifted.
&mdash; Craig Fuller &#x1f6e9;&#x1f69b;&#x1f682;&#x2693;&#xFE0F; (@FreightAlley) <a href="https://twitter.com/FreightAlley/status/1915970424648708338?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">Trading That Thesis&nbsp;</h2>
It&#8217;s a bearish thesis, so we&#8217;ve mainly focused on adding short exposure, with some exceptions. If something looks cheap&#8211;and likely to appreciate, we go long. And we do so on a day when the market is down. We did just that last Monday, placing long term, bullish bets on two Bitcoin-related names. 
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-bitcoin-bull"><img loading="lazy" decoding="async" width="920" height="842" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull.jpg" alt="" class="wp-image-11682" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull.jpg 920w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull-300x275.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071408/Bitcoin-Bull-768x703.jpg 768w" sizes="(max-width: 920px) 100vw, 920px" /></a></figure>
We explained our logic there:&nbsp;
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"><h2 class="wp-block-heading">Why Bitcoin?</h2>
Because Bitcoin is starting to behave like its own asset class, instead of like a more volatile version of the Nasdaq. While the NASDAQ 100-tracking Invesco QQQ Trust (QQQ) is down about 3% as I type this, Bitcoin is up about 2.5%.
<h2 class="wp-block-heading">Why These Two Stocks?</h2>
Because they are both profitable and cheap, with most of their market caps backed by cash and crypto:
<h3 class="wp-block-heading">Company A</h3>
<ul>
<li>Bitcoin Holdings: 742.1 BTC, valued at approximately $69.3 million</li>
<li>Ethereum Holdings: 27,623.9 ETH, valued at approximately $92.1 million</li>
<li>Cash and Cash Equivalents: Approximately $98.6 million</li>
<li>Total Market Capitalization: Approximately $325 million</li>
</ul>
Asset Composition Relative to Market Cap:
<ul>
<li>Bitcoin and Ethereum: ~50%</li>
<li>Cash: ~30%</li>
<li>Combined Liquidity (BTC + ETH + Cash): ~80%</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">Company B</h3>
<ul>
<li>Bitcoin Holdings: 2,298 BTC, valued at approximately $214.6 million</li>
<li>Cash and Cash Equivalents: Approximately $8.9 million</li>
<li>Total Market Capitalization: Approximately $295 million</li>
</ul>
Asset Composition Relative to Market Cap:
<ul>
<li>Bitcoin: ~73%</li>
<li>Cash: ~3%</li>
<li>Combined (BTC + Cash): ~76%</li>
</ul>
</blockquote>
Company B was Semler Scientific, Inc. (SMLR), and it finished the week up more than 15%. 
<h2 class="wp-block-heading">Mostly Bearish Bets The Rest Of The Week</h2>
The rest of the week, we mainly added short exposure on market rallies. Specifically, we placed bets against:&nbsp;
<ul>
<li>High yield bonds, via the iShares iBoxx $ High Yield Corporate Bond ETF (HYG)</li>
<li>Trucking companies serving our ports.&nbsp;</li>
<li>Freight forwarders serving American small businesses importing from China.&nbsp;</li>
<li>Other vendors serving those small business.&nbsp;</li>
</ul>
We wrapped up the week with another bet against&nbsp;Nvidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) as it bounced above $110.&nbsp;
<figure class="wp-block-image size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-fading-the-rally-again"><img loading="lazy" decoding="async" width="922" height="815" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again.jpg" alt="" class="wp-image-11683" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again.jpg 922w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again-300x265.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071815/Nvidia-Again-768x679.jpg 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h2 class="wp-block-heading">Balancing Fear And Greed&nbsp;</h2>
We ended the week with three profitable exits, two on bearish trades (including an earlier bet against Nvidia), and one on a bullish put spread on&nbsp;Celestica, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>).&nbsp;
Options
<ol>
<li>Puts on Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). Bought for $1.81 on 4//14/2025; sold for $2.71 on 4/21/2025. Profit: 50%.</li>
<li>Put spread on Celestica (CLS 0.61%↑). Entered at a net credit of $3.12 on 3/27/2025; exited at a net debit of $2 on 4/25/2025. Profit: 59.6%.</li>
<li>Puts on Nvidia (NVDA -2.83%↓). Bought for $1.56 on 4/9/2025; sold for $4.02 on 4/21/2025. Profit: 158%.</li>
</ol>
Although we were bearish on Monday, we nevertheless decided to take profits on Apple and Nvidia again, as those options were expiring on Friday. In that case, our fear outweighed our greed, and enabled us to have three profitable exits this week instead of just one. We post our trade exits at the end of each week, including our losses. This week, we didn&#8217;t have any exits for losses, which was a welcome change from the previous week.&nbsp;
If you would like to trade alongside us next time, you can subscribe to our trading Substack/occasional email list below.&nbsp;
And if you just want to add some downside protection here,&nbsp;you can download the Portfolio Armor optimal hedging app by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you&#8217;re reading this on your phone). Our app can help you find the least expensive hedges given your risk tolerance and time frame.
<figure class="wp-block-image size-full"><a href="158%. Although we were bearish on Monday, we nevertheless decided to take profits on Apple and Nvidia again, as those options were expiring on Friday. In that case, our fear outweighed our greed, and enabled us to have three profitable exits this week instead of just one. We post our trade exits at the end of each week, including our losses. This week, we didn't have any exits for losses, which was a welcome change from the previous week. If you would like to trade alongside us next time, you can subscribe to our trading Substack/occasional email list below. And if you just want to add some downside protection here, you can download the Portfolio Armor optimal hedging app by aiming your iPhone camera at the QR code below (or by tapping here, if you're reading this on your phone). Our app can help you find the least expensive hedges given your risk tolerance and time frame."><img loading="lazy" decoding="async" width="200" height="197" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26071945/QR-Code-3-3.jpg" alt="" class="wp-image-11684" /></a></figure>
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26072116/Widget-6.jpg" alt="" class="wp-image-11685" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26072116/Widget-6.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26072116/Widget-6-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Options

Opinion

Trading Ideas

AAPL

NVDA

Navigating A Roller Coaster Market

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains WSFS Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>) with a Market Perform and lowers the price target from $66 to $64.

WSFS

Keefe, Bruyette & Woods Maintains Market Perform on WSFS Financial, Lowers Price Target to $64

WIIM

ABBV

AbbVie shares are trading higher after multiple analysts raised their price targets on the stock. The company last week reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains USCB Financial Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USCB#NASDAQ">USCB</a>) with a Outperform and lowers the price target from $23 to $21.

USCB

Keefe, Bruyette & Woods Maintains Outperform on USCB Financial Holdings, Lowers Price Target to $21

Macro Economic Events

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are lower as NVIDIA falls following reports indicating China's Huawei Technologies has developed an AI chip to challenge the company. Ongoing trade uncertainty may also be driving continued market volatility.

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains United Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBSI#NASDAQ">UBSI</a>) with a Market Perform and lowers the price target from $42 to $40.

UBSI

Keefe, Bruyette & Woods Maintains Market Perform on United Bankshares, Lowers Price Target to $40

Eli Lilly shares are trading lower after HSBC downgraded the stock from Buy to Reduce and lowered the price target from $1,150 to $700.

Keefe, Bruyette &amp; Woods analyst Kelly Motta maintains TriCo Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBK#NASDAQ">TCBK</a>) with a Market Perform and lowers the price target from $48 to $46.

TCBK

Keefe, Bruyette & Woods Maintains Market Perform on TriCo Bancshares, Lowers Price Target to $46

Goldman Sachs analyst Neil Mehta upgrades Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) from Sell to Neutral and raises the price target from $115 to $127.

Goldman Sachs Upgrades Valero Energy to Neutral, Raises Price Target to $127

Keefe, Bruyette &amp; Woods analyst Timothy Switzer maintains Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) with a Outperform and lowers the price target from $72 to $70.

TBBK

Keefe, Bruyette & Woods Maintains Outperform on Bancorp, Lowers Price Target to $70

SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) shares are trading higher on Monday after the company inked a deal to be acquired by Merck &amp; Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45031957/merck-kgaa-darmstadt-germany-to-acquire-springworks-therapeutics-to-accelerate-sustainable-growth-" rel="noreferrer noopener">for $47 per share in cash</a>.
The acquisition price translates to an equity value of around $3.9 billion and an enterprise value of $3.4 billion (3.0 billion euros), based on SpringWorks' cash position of $461.9&nbsp;million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43843001/springworks-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlight" rel="noreferrer noopener">as of December 31, 2024</a>.
As per media reports in February, Merck Germany reacted to press reports and confirmed advanced discussions <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43631130/germanys-merck-in-talks-to-buy-cancer-drug-maker-springworks-therapeutics" rel="noreferrer noopener">with&nbsp;SpringWorks Therapeutics</a>.
The offer represents a 26% premium over SpringWorks' 20-day volume-weighted average share price of $37.38 as of February 7, 2025, the day before initial market rumors of a potential acquisition surfaced.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43661635/springworks-therapeutics-secures-fda-approval-for-second-cancer-drug" rel="noreferrer noopener">SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug</a>
The deal will be financed through a combination of available cash and newly issued debt.
The acquisition aligns with Merck, Darmstadt, Germany's Healthcare division strategy, as detailed during its Capital Markets Day in October 2024, which emphasizes sourcing external innovation through licensing high-quality assets at various development stages and pursuing selective acquisitions that offer early value creation.
Additionally, the move supports the company's strategic aim to expand its Healthcare presence in the United States.
The acquisition, unanimously approved by both companies' boards, is expected to close in the second half of 2025, subject to shareholder and regulatory approvals.
As of December 31, 2024, Merck Germany <a target="_blank" href="https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2024-q4/en/2024-Q4-Report-EN.pdf" rel="noreferrer noopener">had</a> cash and cash equivalents of 2.52 billion euros.
Synergies: Once completed, the acquisition is expected to immediately contribute to Merck's revenue and become accretive to<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> its earnings per share pre by 2027</a>.
Notably, SpringWorks' portfolio of rare tumor treatments, including a first-in-class, systemic standard-of-care therapy for adults with desmoid tumors and the only approved treatment for adults and children with symptomatic plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1), is projected to drive immediate and sustainable revenue growth for Merck KGaA, Darmstadt, Germany.
In November 2023, The FDA approved&nbsp;SpringWorks Therapeutics' Ogsiveo (nirogacestat), an oral gamma-secretase inhibitor, for adult patients with progressing desmoid tumors who&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35974211/fda-approves-springworks-therapeutics-lead-therapy-as-first-for-subtype-of-soft-tissue-sarcomas" rel="noreferrer noopener">require systemic treatment</a>.
Ogsiveo is the&nbsp;<a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-type-non-cancerous-tumors" rel="noreferrer noopener">first&nbsp;</a>drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas.
Ogsiveo net product revenues were $61.5 million and $172.0 million in the fourth quarter of 2024 and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43843001/springworks-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-highlight" rel="noreferrer noopener">full year 2024, respectively</a>.
Peter Guenter, member of the Executive Board and CEO of Healthcare at Merck KGaA, Darmstadt, Germany, said, "Together, Merck KGaA, Darmstadt, Germany and SpringWorks are the perfect combination to improve outcomes for patients with rare tumors and bring therapeutic innovations to more patients worldwide while building on and reinforcing the early success of SpringWorks in the United States."
Last week, SpringWorks disclosed that its marketing authorization application (MAA) for FDA-approved treatment, OGSIVEO (nirogacestat) is currently under review by the European Medicines Agency (EMA), with a decision from the Committee for Medicinal Products for Human Use (CHMP) anticipated <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45029219/springworks-therapeutics-announces-expected-chmp-opinion-in-q2-2025-for-nirogacestat-for-the-treat" rel="noreferrer noopener">in the second quarter of 2025</a>.
Investors can gain exposure to the stock via&nbsp;iShares Genomics Immunology and Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDNA#NYSE">IDNA</a>) and Virtus LifeSci Biotech Products ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBP#NYSE">BBP</a>).
Price Action: SWTX shares are trading higher by 3.20% at $46.15 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/45021274" target="_blank" rel="noreferrer noopener">Merck Stays Confident On M&amp;A Despite Market Uncertainty: Analyst</a></li>
</ul>
Photo via Shutterstock

Earnings

Mid Cap

Guidance

Movers

IDNA

SWTX

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintains Stellar Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEL#NYSE">STEL</a>) with a Market Perform and lowers the price target from $31 to $29.

STEL

Keefe, Bruyette & Woods Maintains Market Perform on Stellar Bancorp, Lowers Price Target to $29

Saia Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAI#NASDAQ">SAI</a>) reported results that "shocked even the bears," with significantly worse-than-expected yields, according to JPMorgan.
The Saia Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58502bcfee7bf6000190795f/brian-ossenbeck">Analyst Brian Ossenbeck</a> maintained an Overweight rating, while slashing the price target from $436 to $299.
The Saia Thesis: Faced with pricing pressure due to intensifying competition, the higher weight per shipment did little to support margins and adversely impacted headline revenue," Ossenbeck said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Contract renewals decelerated, with "customers shifting to other options," the analysts stated. Peers like TFI International rebuilt its network with small and medium businesses or scaled into larger network from scratch, like Knight-Swift Transportation Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>), he added.
Rival XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) may announce its second-quarter guidance closer to consensus expectations, given the "combination of self-help initiatives in cost savings and less net new door capacity additions compared to Saia," Ossenbeck further wrote.
SAI Price Action: Shares of Saia had declined by 2.91% to $238.47 at the time of publication on Monday.
Read More: • <a href="https://www.google.com/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=newssearch&amp;cd=&amp;cad=rja&amp;uact=8&amp;ved=2ahUKEwj2hvfI_fqMAxXER2wGHWLEOIsQxfQBKAB6BAgJEAE&amp;url=https%3A%2F%2Fwww.benzinga.com%2Fnews%2Fearnings%2F25%2F04%2F44937938%2Fcapital-one-reports-mixed-q1-results-eps-beat-revenue-misses&amp;usg=AOvVaw3g8PTc3dpKR3V3BTnwdyaP&amp;opi=89978449">J.B. Hunt Transport Overcorrects Into a Buying Opportunity</a>
Photo: Shutterstock

Analyst Color

Earnings Misses

Reiteration

Saia's Q1 'Shocked Even The Bears': Analyst Slashes Price Target, Compares Fundamentals With Peers

Keefe, Bruyette &amp; Woods analyst Michael Perito maintains S&amp;T Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBA#NASDAQ">STBA</a>) with a Market Perform and lowers the price target from $44 to $43.

STBA

Keefe, Bruyette & Woods Maintains Market Perform on S&T Bancorp, Lowers Price Target to $43

RBC Capital analyst Victoria McCulloch reiterates TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>) with a Outperform and maintains $37 price target.

RBC Capital Reiterates Outperform on TechnipFMC, Maintains $37 Price Target

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 15 years by 1.47% on an annualized basis producing an average annual return of 12.27%. Currently, Union Pacific has a market capitalization of $127.24 billion. 
Buying $100 In UNP: If an investor had bought $100 of UNP stock 15 years ago, it would be worth $550.77 today based on a price of $212.96 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745856912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith maintains RE/MAX Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMAX#NYSE">RMAX</a>) with a Market Perform and lowers the price target from $10 to $9.

RMAX

Keefe, Bruyette & Woods Maintains Market Perform on RE/MAX Holdings, Lowers Price Target to $9

Small Cap

Press Releases

ZK International Group Co., Ltd. Announces Record Revenue of $52.89 Million, an Increase of 6.5% for the First Half of Fiscal Year 2024

Micro Cap Outperforms Broader Market Following H1 Revenue Results

Commodities

Contracts

ZK International Group's Breakthrough Win in the Shenzhen Gas Project is Expected to Propel Growth Amid China's Economic Stimulus Which Should Exceed $284 Billion

Comments

ZK International Gr Co

ZK International Gr Co (ZKIN) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL